Opko Health Inc. (NASDAQ:OPK) was down 0% on Tuesday . The stock traded as low as $4.55 and last traded at $4.60. Approximately 8,004,178 shares were traded during trading, an increase of 135% from the average daily volume of 3,409,381 shares. The stock had previously closed at $4.60.

Several equities research analysts recently weighed in on OPK shares. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 23rd. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $16.00 price objective on shares of Opko Health in a research report on Monday, September 25th. Zacks Investment Research cut shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the stock a “buy” rating in a research report on Thursday, October 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.34.

The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. The company has a market cap of $2,570.00, a P/E ratio of -24.21 and a beta of 1.82.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The business had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The firm’s revenue was down 11.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) EPS. research analysts anticipate that Opko Health Inc. will post -0.27 EPS for the current year.

In other news, major shareholder Opko Health, Inc. acquired 655,738 shares of the stock in a transaction dated Monday, October 30th. The stock was bought at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the purchase, the insider now directly owns 6,678,752 shares of the company’s stock, valued at approximately $20,370,193.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 40.19% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in OPK. Dimensional Fund Advisors LP increased its position in Opko Health by 127.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock valued at $27,466,000 after purchasing an additional 2,241,103 shares during the period. Cornerstone Capital Management Holdings LLC. increased its position in Opko Health by 611.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock valued at $9,913,000 after purchasing an additional 1,242,272 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its position in Opko Health by 83.7% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,579,950 shares of the biotechnology company’s stock valued at $17,698,000 after purchasing an additional 1,175,726 shares during the period. Schwab Charles Investment Management Inc. increased its position in Opko Health by 43.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock valued at $10,746,000 after purchasing an additional 471,256 shares during the period. Finally, State Street Corp increased its position in Opko Health by 3.9% during the 2nd quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock valued at $74,671,000 after purchasing an additional 422,203 shares during the period. 22.91% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/opko-health-opk-trading-down-0/1810013.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.